TV
TVGN
Tevogen Bio Holdings Inc.
$10.12
-3.44%
$43.9M
No data for this timeframe.
Vol
Market Cap$43.9M
Cap SizeNano Cap
Analyst ConsensusSell (0%)
Inst. Holders6 funds
Inst. Value$542.4K
Inst. Activity3 buys / 0 sells
Insider Activity0B / 3S
Insider Net $-$6.6K
Reddit Sentiment58° Warm
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001860871·Prev Close $10.48
Recent Activity
Mar 13, 2026
Insider
Flomenberg Neal sold 501 shares
See Remarks @ $6.40 ($3.2K)
Mar 11, 2026
Insider
Flomenberg Neal sold 452 shares
See Remarks @ $7.26 ($3.3K)
Mar 10, 2026
Insider
Flomenberg Neal sold 19 shares
See Remarks @ $7.75 ($147.25)
Inst.
MORGAN STANLEY — ADD
250,258 shares ($82.9K)
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
45,483 shares ($15.1K)
May 18, 2026
other
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth,
Mar 25, 2026
Press
Tevogen Bio (TVGN) announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, resolving a d
Impact 4/10
Mar 9, 2026
Press
Tevogen Bio announced the appointment of interim leaders across key business units as part of its diversified growth str
Impact 4/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 4, 2026 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Mar 3, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $375.3K | DOUBLED |
| MORGAN STANLEY | $82.9K | ADD |
| FMR LLC | $33.7K | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $27.2K | ADD |
| WELLS FARGO & COMPANY/MN | $15.1K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 13, 2026 | Flomenberg Neal | SELL | $3.2K |
| Mar 11, 2026 | Flomenberg Neal | SELL | $3.3K |
| Mar 10, 2026 | Flomenberg Neal | SELL | $147.25 |
Reddit Sentiment
58°
Warm
Bearish
Neutral
Bullish
6 institutional holders with $542.4K total value (1,638,375 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, FMR. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,133,745 | $375.3K | 69.2% | DOUBLED +617.0% |
| 2 | MORGAN STANLEY | 250,258 | $82.9K | 15.3% | ADD +97.6% |
| 3 | FMR LLC | 101,914 | $33.7K | 6.2% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 82,114 | $27.2K | 5.0% | ADD +54.0% |
| 5 | WELLS FARGO & COMPANY/MN | 45,483 | $15.1K | 2.8% | DOUBLED +123.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 24,861 | $8.2K | 1.5% | ADD +80.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 126,656 | 250,258 | +97.6% | $82.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 20,336 | 45,483 | +123.7% | $15.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 13,811 | 24,861 | +80.0% | $8.2K | 2025-Q4 |
| UBS Group AG | TRIM | 81,120 | 40,897 | -49.6% | $32.1K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 16,202 | 20,336 | +25.5% | $16.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 65,901 | 148,922 | +126.0% | $186.2K | 2025-Q2 |
| UBS Group AG | TRIM | 183,858 | 81,120 | -55.9% | $101.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 49,644 | 76,475 | +54.0% | $95.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 12,357 | 16,202 | +31.1% | $20.3K | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 145,202 | 1,041,075 | +617.0% | $1.1M | 2025-Q1 |
1 unique insiders with 3 transactions. Net insider value: -$6.6K ($0.00 bought, $6.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Flomenberg Neal | See Remarks | SELL | 501 | $6.40 | $3.2K |
| Mar 11, 2026 | Flomenberg Neal | See Remarks | SELL | 452 | $7.26 | $3.3K |
| Mar 10, 2026 | Flomenberg Neal | See Remarks | SELL | 19 | $7.75 | $147.25 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
NEUTRAL
4/10
Tevogen Bio (TVGN) announced it has regained compliance with Nasdaq's $1.00 minimum bid price requir
Mar 25, 2026
NEUTRAL
4/10
Tevogen Bio announced the appointment of interim leaders across key business units as part of its di
Mar 9, 2026
NEUTRAL
4/10
Tevogen Bio (TVGN) announced a non-binding Letter of Intent to evaluate a potential acquisition of A
Mar 5, 2026
Current analyst consensus: Strong Sell (0% buy). Based on 6 analysts: 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 4, 2026 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Mar 3, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
58°
Warm
Bearish
Neutral
Bullish
2 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Oct 18, 2024 | 1 | 44° Neutral | 0 | 0 | 1 |
| Oct 15, 2024 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
other
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.
May 13, 2026
earnings_calendar
TVGN Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
other
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen Bio announces $3 million PIPE financing with The Patel Family, LLP to support growth initiatives and future revenue opportunities.
May 12, 2026
earnings_calendar
TVGN Q1 2026 Earnings Scheduled — 2026-05-12
Apr 27, 2026
other
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen.AI nears PredicTcell completion, expands features to 290+, improves precision ~10%, and begins exploring co-development partnerships.
Mar 26, 2026
other
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen advances CRO evaluation to drive $20M+ revenue growth, expand global clinical capabilities, and support a scalable, cash-flow-oriented model.
Mar 25, 2026
activist
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen regains compliance with Nasdaq minimum bid price requirement.
Mar 25, 2026
earnings_calendar
TVGN Q4 2025 Earnings Scheduled — 2026-03-25
Mar 18, 2026
other
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen.AI head Mittul Mehta to speak at FabCon 2026 on agentic AI and adaptive data pipelines, advancing enterprise-ready intelligent data systems.
Mar 13, 2026
other
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset v
Mar 13, 2026
other
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
<p>WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=sC4EbPc4EVMldfs1Eab5su7yC5j_RxMlq7FlXSV7NE6y
Mar 11, 2026
other
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen advances TVGN 489 for Long COVID, expanding HLA coverage to 65% of U.S. population and integrating digital monitoring capabilities.
Mar 9, 2026
earnings
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen names interim leaders to advance diversified growth strategy and evaluate subsidiaries targeting $50M+ in annual revenue.
Mar 6, 2026
other
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen CEO outlines potential subsidiary acquisitions targeting $50M+ revenue and positive cash flow to support long-term growth.
Mar 5, 2026
m_and_a
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen signs LOI to evaluate Apozeal acquisition, advancing U.S.-focused generics strategy with 10 FDA-approved ANDAs and pipeline assets.